ACAD241220P13000
- 0.10
- 0.000.00%
ACADIA Pharmaceuticals Newsroom
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
CCORF Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $32
ACADIA Pharmaceuticals: Strategic Leadership and Growth Prospects Support Buy Rating
Acadia Pharmaceuticals Announces Leadership Change Amid COO Departure
Express News | ACADIA Pharmaceuticals Inc - on Nov 18, Co Involuntarily Terminates COO Brendan Teehan
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | ACADIA Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business
CCORF Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Cuts Target Price to $32
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $18 to $39
ACADIA Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations
ACADIA Pharmaceuticals: Strong Buy Rating Backed by Promising Growth and Undervalued Assets
ACADIA Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Stifel Nicolaus Reaffirms Their Hold Rating on ACADIA Pharmaceuticals (ACAD)
Acadia's Q3 Earnings Beat, Nuplazid & Daybue Drive Revenue Growth
Express News | ACADIA Pharmaceuticals Inc : Canaccord Genuity Cuts Target Price to $32 From $33
ACADIA Pharmaceuticals Price Target Maintained With a $28.00/Share by Needham
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $20 to $39
ACADIA Pharmaceuticals Analyst Ratings
Buy Rating for ACADIA Pharmaceuticals Amid Strong Financial Performance and Growth Prospects